A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

Trial Profile

A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications T-cell leukaemia
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 12 Sep 2016 Results assessing efficacy and safety of lenalidomide monotherapy in patients with T-Cell leukemia/lymphoma published in the Journal of Clinical Oncology.
    • 04 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2017, according to ClinicalTrials.gov record.
    • 04 Jan 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top